Immune evasion is a hallmark of cancer, contributing signifcantly to the progression of malignancies and associated mortalities. An interdisciplinary approach lead by acib can assess personalized treatment options for patients, as well as lay the foundation to designing novel treatments
Background
acib is leading a multi-disciplinary approach combining wet-lab human DLBCL patient-derived co-culture experiments with next generation sequencing and sophisticated bioinformatic analyses. The aim is to i) test for the best combinational therapy options ex vivo and ii) to discover transcriptional and immunological signatures characterizing patients as candidates for targeted therapies. This approach towards precision oncology will allow a personalized selection of treatment options for each patient and offer important considerations for the design of novel treatments.
acib has ample expertise in providing R&D services to various companies – check also our other project offers
Technology
Project Offer
acib offers to develop tools for efficient combinational therapies targeting DLBCL and to discover new cancer signatures for novel therapeutics. IP developed in such projects will be fully transferred to you as our investor/industrial partner.